Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Urogen Pharma, retaining the price target of $40.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Ram Selvaraju has given his Buy rating due to a combination of factors, primarily driven by the promising commercial trajectory of UroGen Pharma’s ZUSDURI. Since its launch, the drug has shown significant momentum with a growing number of activated care sites and prescribers. The recent assignment of a permanent J Code by CMS is expected to streamline reimbursement processes, potentially reducing the time from patient enrollment to authorization, which could further accelerate ZUSDURI’s market uptake.
Additionally, UroGen’s financial health supports this positive outlook, with the company on track to achieve cash flow-positive status by late 2026. Despite a slight miss in third-quarter revenue expectations, UroGen’s overall commercial execution aligns with forecasts, and the company maintains a strong cash position. The ongoing development of UGN-103, with promising clinical trial results, further bolsters the company’s future prospects, justifying the Buy rating and a 12-month price target of $40.
In another report released on November 7, Ladenburg Thalmann & Co. also reiterated a Buy rating on the stock with a $55.00 price target.